Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Antônio Bernardo et al.|The Lancet Oncology|2018Cited by 88
“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Filippo Montemurro, Laura Pizzuti et al.|Oncotarget|2016Cited by 43
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Giammarco Surico, Alessandra Fabi et al.|Breast Cancer Research and Treatment|2017Cited by 12
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Nicola Tinari, Eriseld Krasniqi et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in EuropeLuca Moscetti, Federico Piacentini, Isabella Sperduti et al.|The Breast|2021Cited by 10